• Progenics Pharmaceuticals Inc., of Tarrytown, N.Y., acquired Molecular Insight Pharmaceuticals Inc., of Cambridge, Mass. Under the terms of the all-stock transaction, Progenics exchanged about 4.5 million shares of its common stock (8.9 percent of the total outstanding post-transaction shares) for all of the outstanding shares of Molecular Insight, which will become a wholly owned subsidiary of Progenics.